Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Gavocabtagene autoleucel |
| Trade Name | |
| Synonyms | Gavo-cel|TC 210|TC-210|TC210 |
| Drug Descriptions |
Gavocabtagene autoleucel are T-cells engineered to express an anti-mesothelin (MSLN) antibody linked to a CD3 epsilon subunit, with potential activity against MSLN-expressing tumors (Cancer Res 2021;81(13_Suppl):Abstract nr CT105). |
| DrugClasses | MSLN Immune Cell Therapy 10 |
| CAS Registry Number | NA |
| NCIT ID | C160780 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Gavocabtagene autoleucel | Gavocabtagene autoleucel | 0 | 1 |
| Gavocabtagene autoleucel + Ipilimumab + Nivolumab | Gavocabtagene autoleucel Ipilimumab Nivolumab | 0 | 1 |
| Gavocabtagene autoleucel + Nivolumab | Gavocabtagene autoleucel Nivolumab | 0 | 1 |